A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
Part of paid clinical trials in Houston, Texas.
- Sponsor
- BioNTech SE
- Study ID
- NCT07698600
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- HIV -1 Infection
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- BNT168 — BIOLOGICALIntramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections
- Placebo — OTHERIsotonic sodium chloride (NaCl) solution (0.9%). Intramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections
Study Details
This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.
Key Dates
- First listed
- Jul 13, 2026
- Start date
- Aug 4, 2026
- Status verified
- Aug 2026
- Primary completion
- Feb 29, 2028
- Completion
- Feb 29, 2028
Study Design
- Enrollment
- 126 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: A1 in PLWOH - BNT168 dose level 1
- Experimental: A2 in PLWOH - BNT168 dose level 2
- Experimental: A3 in PLWOH - BNT168 dose level 3
- Experimental: A4 in PLWH - BNT168 dose level 2This cohort will undergo ATI post vaccination
- Experimental: A5 in PLWH - BNT168 dose level 3This cohort will undergo ATI post vaccination
- Placebo Comparator: PLWOH - Placebo
- Placebo Comparator: PLWH - PlaceboPLWH participants receiving placebo will also undergo ATI post vaccination
Primary Outcome Measure
Occurrence of at least one adverse event [ Time Frame: From dosing through 28 days after each IMP dose ]
Central Contacts
- BioNTech clinical trials patient information+49 6131 9084
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The Crofoot Research Center | Houston | Texas | 77098 | - |
Find similar trials in Houston, TX
By research site
Related Studies
- Cabotegravir & Rilpivirine Antiretroviral Therapy in PregnancyNot Yet Recruiting · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · La Jolla, California
- Safety Study of MucoCept-CVNPHASE1 · Recruiting · Craig Cohen, MD, MPH · San Francisco, California
- A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIVPHASE1 · Recruiting · BioNTech SE · Chicago, Illinois
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidEPHASE4 · Recruiting · CAN Community Health · Clearwater, Florida